Abstract: The invention relates to novel methods for making oil-in-water emulsions having mucoadhesive properties which are primarily intended for administration of biologically active compounds to mucosal surfaces. The emulsion has an aqueous continuous phase and a plurality of submicron particles having an average particle diameter of from 10 nm to 600 nm, with the particles having a hydrophobic phase of a fat or oil which forms a hydrophobic core that is surrounded by a surfactant layer. The emulsion further includes a mucoadhesive polymer which is a polymer or copolymer of acrylic acid or methacrylic acid, a poly (methyl vinyl ether/maleic anhydride) copolymer, pectin, alginic acid, hyaluronic acid, chitosan, gum tragacanth, karaya gum or carboxymethylcellulose surrounding the hydrophobic one. A biologically active compound may also be included, if desired.

Abstract: A method and composition for treating outbreaks of acne. Initially, the acne affected area is cleaned. A topical spray comprising about 1 to 10 wt % niacinamide, about 0.1 to 1 wt % Aloe Vera extract and about 0.1 to 1 wt % NaPCA in a water carrier is then applied to the area. Generally, at least two spray applications are made each day. For optimum skin cleaning, an exfoliation scrub such as a conventional apricot facial scrub is preferably applied to the skin prior to application of the combination topical spray.

Abstract: Sticky dental compositions which include a sticky, glue-like matrix material for treating a variety of tooth or gum ailments, and methods for treating teeth using such compositions. For maximum comfort, an improved dental tray that is thin-walled, flexible and lightweight is used to hold the sticky dental composition adjacent the desired tooth surfaces. The sticky dental compositions include a sticky matrix material into which is dispersed an appropriate dental agent, such as a bleaching agent, a desensitizing agent, and an anticariogenic agent, an antimicrobial agent. The matrix material preferably includes carboxypolymethylene that has been partially neutralized with a base to reduce etching of the enamel. The carboxypolymethylene adds a unique stickiness to the dental composition which helps to adhere and retain the soft tray material against the person's teeth.

Abstract: The present invention relates to an oral delivery system containing a group c streptococcal phage associated lysin enzyme for the prophylactic and therapeutic treatment of Streptococcal A throat infections, commonly known as strep throat.

Abstract: A coated product in the form of solid particles of a food or pharmaceutical wherein the particles are each coated with a water-soluble hemicellulose. The water-soluble hemicellulose has a viscosity in the range of from 50 to 1,000 mPa.multidot.s at 25.degree. C. when dissolved in water in an amount of 10% by weight and has a reducing sugar content of 5% by weight or less and an amino acid content, as measured by assay with 2,4,6-trinitrobenezene sulfonic acid, of 1.0% by weight or less.

Abstract: Formation of a drug into microspheres by an oil-on-water solvent evaporation process in which a mixed solvent of at least one water-insoluble solvent and at least one water-miscible solvent is used as a solvent of an oil phase. A fatty acid or a salt thereof or at least one glycerin fatty acid ester and/or at least one propylene glycol fatty acid ester are added to the mixed solvent. The oil phase may also comprise the mixed solvent; a fatty acid or a salt thereof; and at least one glycerin fatty acid ester and/or at least one propylene glycol fatty acid ester. This oil phase is mixed and emulsified with an aqueous phase to form an oil-in-water emulsion. The emulsion with a drug contained therein is then subjected to an oil-in water solvent evaporation to produce the microspheres. The resulting drug-containing microspheres contain the drug at a high concentration and slowly release from the initial stage after administration.

Abstract: A method of treating a mammalian patient suffering from or prone to a condition characterized by late phase allergic reactions, airway hyperresponsiveness or inflammatory reactions, e.g., asthma, allergic rhinitis, allergic dermatitis, allergic conjunctivitis, inflammatory bowel disease or rheumatoid arthritis, comprising the administration to the patient of an oral, parenteral, intrabronchial, topical, intranasal or intraocular pharmaceutical composition containing in each dose about 0.005 to about 1.0 mg per kilogram of patient body weight of ultra-low molecular weight heparins (ULMWH) or other sulfated polysaccharides having average molecular weights of about 1,000-3,000 daltons. Suitable inhalant and other pharmaceutical compositions for use in the novel treatment method are also disclosed.

Abstract: Pharmaceutical aerosol formulations comprising flunisolide, ethanol, and a propellant selected from the group consisting of 1,1,1,2-tetrafluoroethane, 1,1,1,2,3,3,3-heptafluoropropane, and a mixture thereof.

Abstract: A drug delivery system (10) includes a first capsule half (12) having an inner chamber (16) for containing a drug (18) therein. A plug (28) is disposed in a passageway (26) of the capsule half (12) for plugging the opening (24) thereof. The plug (28) is releasable from the passageway opening (24) upon the application of pressure from within the inner chamber (16). A pump mechanism, reactive with the external environment of the capsule half (12), causes an increase in pressure within the inner chamber (16) and forces the plug (28) out of the passageway (26) to release the drug (18) from the inner chamber (16) and out of the passageway (26). Thusly, after initial release of drug from a second capsule half (14) releasably mounted on the first capsule half (12), the first capsule half (12) provides a second pulse of drug release at a predetermined time after initial ingestion of the capsule.

Abstract: Skin care compositions comprising an oil-in-water emulsion base containing retinoids and possessing good physical and chemical stability. More particularly, said skin care compositions contain (a) an emulsifier system selected from the group consisting of: (i) a mixture of glyceryl stearate and polyethylene glycol 100 stearate; (ii) cetearyl alcohol and cetearyl glucoside; (iii) a mixture of a polyethylene glycol ethers of stearyl alcohol; and (iv) a mixture of sorbitan stearate and polysorbate 60; (b) a co-emulsifier selected from the group consisting of cetyl alcohol, stearyl alcohol and mixtures thereof; (c) an oil phase present in the amount of from about 5 to about 20 percent by weight of the total emulsion composition which contains (i) a light, dry absorbable oil and (ii) substantive, emollient oils or waxes, wherein the light, dry absorbable oil and the substantive oil or wax are present in a ratio of from about 1:3 for about 10:1.

Abstract: A method of cryogenically treating psoriatic lesions. In accordance with the present method, a cryogenic agent is applied by the spray technique to the surface of a psoriatic lesion for a period of time sufficient to "frost" the psoriatic lesion with the duration stopping short of the time necessary to cause formation of a fluid bullae or sloughing off of the affected tissue.

Abstract: Aerosol formulations for topical administration for cooling of mammalian tissues. The formulations are rapid onset and sustained effect, and further contain no CFCs and are nonflammable.

Abstract: A method for treating allergic rhinitis in a patient is disclosed which comprises applying an anti-allergic rhinitis effective amount of a steroid in ointment or creme carrier to the lining of the vestibules of the patient.

Abstract: This invention provides orally administerable pharmaceutical formulations comprising raloxifene, its ethers or esters, or a pharmaceutically-acceptable salt thereof, in combination with a hydrophilic carrier composition.

Abstract: A device for applying a topical anesthetic includes a body to be wrapped around a part of the patient to provide a conformed fit. When wrapped, the body has an inside surface facing the part where a holder for holding a topical anesthetic against the patient's skin is provided and covered with a removable seal. The device can take a number of forms, such as a glove, a sock, or a tube. When wrapped, the device provides a comfortable and snug fit. The device has integral hook and loop regions for easy attachment and removal.

Abstract: A protective cosmetic particulate gel delivery system for a topically applied active agent employs an agar gel and a restraining polymer to retain the actve agent in the gel. The particles have an average particle diameter of at least 0.05 mm while the restraining polymer has a molecular weight of at least 50,000 daltons and has retention groups to bind the active agent. The restraining polymers can be selected from the group consisting of polyquaternium 24, laurdimonium hydroxyethylcellulose, cocodimonium hydroxyethylcellulose, steardimonium hydroxyethylcellulose, quaternary ammonium substituted water-soluble polysaccharides, alleyl quaternary celluloses and polypeptides having or provided with retention groups to retain the active agent. The gel particles of the invention are manually crushable on the skin to increase the surface area of the gel particle material and expose the restraining polymer to the skin or other body surface for release of the active agent.

Abstract: The present invention provides a high dose pharmaceutical liposome aerosol composition comprising about 12-30 mg/ml of a pharmaceutical compound, and about 130-375 mg of a phospholipid/ml starting reservoir concentration. Specifically, the present invention is drawn to anti-inflammatory glucocorticoids, immunosuppressive compounds, anti-fungal compounds, antibiotic compounds, anti-viral compounds, and anti-cancer compounds delivered via a high dose liposome aerosol composition in a phospholipid. More specifically, the invention provides a high dose cyclosporin A liposome aerosol composition comprising up to about 30 mg/ml cyclosporin A in up to about 225 mg of a phospholipid/ml starting reservoir concentration. Also provided is a high dose budesonide-liposome aerosol composition comprising up to about 15 mg/ml budesonide in up to about 225 mg of a phospholipid/ml starting reservoir concentration.

Abstract: A composition is disclosed which is useful in alleviating, at least in part, symptoms of acne vulgaris, psoriasis or seborrhea, which includes a potassium-based compound a dermatologically acceptable base for the potassium-based compound, which is preferably a potassium salt, and which include potassium acetate, potassium aluminate, potassium arsenite solution, potassium bicarbonate, potassium bisulfate potassium bitartararte, potassium bromide, potassium carbonate, potassium chloride, potassium citrate, potassium gluconate, potassium glycerophosphate, potasium iodate, potassium iodide, potassium manganate, potassium permanganate, potassium phosphate monobasic potassium phosphate dibasic, potassium phosphate tribasic, potassium phosphite or a combination thereof. The composition is topically applied to the areas of a patient's skin which are afflicted with any of acne vulgaris, psoriasis or seborrhea.

Abstract: The present invention is concerned with the use of starch containing amylose as a complexant with iodine for preparing dry powder pharmaceutical formulations useful in the preparation of capsules or tablets. The helical structure of the amylose molecule and its ability to complex. with smaller molecules including iodine make starch (amylose) a desirable vehicle for the administration of iodine (I.sub.2) as a dry powder formulation in capsule or tablet form. These pharmaceutical formulations are particularly useful in the treatment of or the prevention of iodine deficiency diseases including breast dysplasia, breast cancer, endometriosis, premenstrual syndrome and radiation sickness from nuclear fallout.

Abstract: Stabilized medicinal aerosol solution formulations comprising medicaments that degrade or decompose by interaction with solvents or water, an HFC propellant, a cosolvent and an acid are described. Further, specific medicinal aerosol solution formulations comprising ipratropium bromide or fenoterol, ethyl alcohol, 1,1,1,2-tetrafluoroethane or 1,1,1,2,3,3,3-heptafluoropropane, and either an inorganic acid or an organic acid are described. The acids are present in amounts sufficient to reduce the degradation of the medicaments to acceptable levels.